SCHEMBL6075869

SCHEMBL6075869

CC(=O)NCC1CCOc2cc(SCc3ccccc3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 18/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
HTR1A P08908 1/20 0.44
KDM6B O15054 6/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6075868 0.92 SMN1; SMN2 (0.44) KDM4CSMN1; SMN2HTR1A
SCHEMBL6077498 0.78 HTR1A (0.43) KDM4CHTR1AKDM6B
SCHEMBL6077048 0.77 MTNR1A (0.44) KDM4CKDM6B
SCHEMBL6076282 0.76 MTNR1A (0.43) KDM4CKDM6B
SCHEMBL21258102 0.75 KDM4C (0.69) KDM4CKDM6B
SCHEMBL5226604 0.74 MTNR1A (0.61) KDM4CHTR1A
SCHEMBL6076769 0.72 MTNR1A (0.48) KDM4CKDM6B
SCHEMBL6077493 0.72 HTR1A (0.43) KDM4CHTR1A
SCHEMBL6077449 0.71 SMN1; SMN2 (0.43) KDM4CSMN1; SMN2HTR1AKDM6B
SCHEMBL21258084 0.71 KDM4C (0.53) KDM4CKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7126012-B2 Substituted cyclic compounds LES LABORATOIRES SERVIER (FR) 2006-10-24 US disclosed
US-7115752-B2 Substituted cyclic compounds LES LABORATOIRES SERVIER (FR) 2006-10-03 US disclosed
US-20050124682-A1 Substituted cyclic compounds LESIEUR DANIEL (FR) 2005-06-09 US disclosed
US-6872851-B1 Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them LES LABORATORIES SERVIER (FR) 2005-03-29 US disclosed
US-20050059729-A1 Substituted cyclic compounds LESIEUR DANIEL (FR) 2005-03-17 US disclosed
EP-1077927-A1 NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ADIR ET COMPAGNIE (FR) 2001-02-28 EP disclosed
WO-1999058495-A1 NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ADIR ET COMPAGNIE (FR) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059729-A1 Substituted cyclic compounds CCNY, CCNT2, TECR KDM4C 1100/4885SMN1; SMN2 4729/4885HTR1A 1875/4885
US-20050124682-A1 Substituted cyclic compounds CCNY, CCNT2, TECR KDM4C 1100/4885SMN1; SMN2 4729/4885HTR1A 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.